Even though dapagliflozin lowered blood pressure, it didn't cause people with type 2 diabetes and healthy kidneys to excrete more salt in their urine when they ate a controlled amount of salt.
Scientific Claim
In patients with type 2 diabetes and preserved kidney function on a standardized sodium intake of 150 mmol/day, dapagliflozin treatment was not associated with significant changes in 24-hour urinary sodium excretion, with mean changes of -7.0 mmol/24h (95% CI: -22.4 to 8.4) after 2-4 days and 2.1 mmol/24h (95% CI: -28.8 to 33.0) after 12-14 days.
Original Statement
“Mean (SD) 24-h sodium excretion at baseline was 150 (32) mmol/24-h, confirming successful design and adherence to the diet. Dapagliflozin treatment did not significantly change 24-h sodium excretion (urinary 24-h sodium change at ST: −7.0 mmol/24-h [95% CI −22.4, 8.4; P = 0.34]; change at ET: 2.1 mmol/24-h [−28.8, 33.0; P = 0.89])”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design is nonrandomized and lacks a control group, so only association can be inferred. The claim correctly uses 'associated with' to reflect this limitation.